

From: "Kesner, Ben., RLD" <Ben.Kesner@state.nm.us>
To: "Swatek, Joshua, DOH" <Joshua.Swatek@state.nm.us>, "Heinz Bennett, Melissa, DOH" <Melissa.Heinz-Bennett@state.nm.us>
Subject: RE: Naloxone
Thread-Topic: Naloxone
Thread-Index: AdCRphXUKQXJa71yRMGrPSrHt5RzsQcW9kHQAADHkfAAANwZCA==
Date: Thu, 21 May 2015 20:56:15 +0000
References: <B6049650E7BD8D44A97BBD23BBC9E5452684F637@CEXMB003.nmes.lcl>
<9520AA9D8760DD499C4A5F25505B795219A150@CEXMB002.nmes.lcl>
Content-Language: en-US
X-MS-Has-Attach:
X-MS-TNEF-Correlator:
Content-Type: multipart/alternative;
boundary="_000_7472697378727672757172686868696974696970807680797070787_"
MIME-Version: 1.0

--_000_7472697378727672757172686868696974696970807680797070787_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

Also, more than likely, if this is approved, the NMMB would approve Naloxone - not opioid antagonist.

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<mailto:ben.kesner@state.nm.us>

www.rld.state.nm.us/pharmacy<http://www.rld.state.nm.us/pharmacy>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-333-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Kesner, Ben., RLD
Sent: Thursday, May 21, 2015 2:55 PM

To: Swatek, Joshua, DOH; Heinz Bennett, Melissa, DOH
Subject: RE: Naloxone

Hi Josh,

I appreciate the thought you put into this. I agree with the majority of your changes.

The part I disagree with is the NM Medical Board.

This is necessary in order to have this type of facility possess opioid antagonist.

I reviewed the statutes and regulations you provided.

And I agree, you can administer Naloxone.

However, the issue is how to have a CBO Licensed Care Facility have authorization to possess a dangerous drug.

Ideally, we would have a legislative change.

But, as we discussed, we possibly could have the NMMB reduce restrictions.

This is still iffy.

Thanks, Ben

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<mailto:ben.kesner@state.nm.us>

www.rld.state.nm.us/pharmacy<http://www.rld.state.nm.us/pharmacy>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-333-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Swatek, Joshua, DOH
Sent: Thursday, May 21, 2015 2:17 PM
To: Kesner, Ben., RLD; Heinz Bennett, Melissa, DOH
Subject: RE: Naloxone

Good Afternoon,

Sorry it has taken me some time to get back with you on this, I've been out of the office due to a family emergency and just got the chance to take a look at it. A lot of it looks very similar to what I had down and didn't get the chance to send out due my time out of the office. I did make a few minor changes to the naloxone section, I'm not comfortable enough with school-based regulations to make changes on that, primarily I simplified the definition of a CBO licensed facility, and moved the limitations of ownership into the CBO section itself. I also removed the NM board standing order portion. To the best of my understanding there is not a standing order needed for the administration of naloxone as there is a statute and regulation that already provides for that with 24-23-1 NMSA 1978 and NMAC 7.32.7. I also removed mention of naloxone and replaced it with opioid antagonist, again this would allow for another potential antagonist to be used if one became available and would not force a regulation change. I hope this all makes sense and thank you so much for working on this Ben. If there are any questions please feel free to let me know and I will be more than happy to answer them for you. I hope you have a great day and again I apologize for the delay.

Thank you,

Josh

From: Kesner, Ben., RLD
Sent: Monday, May 18, 2015 2:08 PM
To: Heinz Bennett, Melissa, DOH; Swatek, Joshua, DOH
Subject: Naloxone

Hello,

Attached are my proposed regulation changes.

It contains more than adding Naloxone.

Please review the Naloxone sections.

Let me know if you have any suggestions, questions or comments.

Thank you, Ben

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<mailto:ben.kesner@state.nm.us>

www.rld.state.nm.us/pharmacy<http://www.rld.state.nm.us/pharmacy>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-33-3-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

--_000_7472697378727672757172686868696974696970807680797070787_

Content-Type: text/html; charset="us-ascii"

Content-Transfer-Encoding: quoted-printable

<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-microsoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>

<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dus-ascii">

<meta name=3D"Generator" content=3D"Microsoft Word 14 (filtered medium)">

<style><!--

```

/* Font Definitions */
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />

```

</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=3D"EN-US" link=3D"blue" vlink=3D"purple">
<div class=3D"WordSection1">
<p class=3D"MsoNormal">Also, more than likely=
, if this is approved, the NMMB would approve Naloxone – not opioid a=
ntagonist.<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa=
n></p>
<div>
<p class=3D"MsoNormal">Ben Kesner<o:p></o:p><=
/span></p>
<p class=3D"MsoNormal">Executive Director<o:p>
></o:p></p>
<p class=3D"MsoNormal">Regulation and Licensi=
ng Department<o:p></o:p></p>
<p class=3D"MsoNormal">New Mexico Board of Ph=
armacy<o:p></o:p></p>
<p class=3D"MsoNormal">(505) 222-9838 - Offic=
e<o:p></o:p></p>
<p class=3D"MsoNormal">(505) 222-9845 - Fax<o=
p></o:p></p>
<p class=3D"MsoNormal"><a href=3D"mailto:ben.=
kesner@state.nm.us">ben.kesner@state.nm.us<o:p></o:p></p>
<p class=3D"MsoNormal"><a href=3D"http://www.=
rld.state.nm.us/pharmacy">www.rld.state.nm.us/pharmacy<o:p></o:p>
></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa=
n></p>
<p class=3D"MsoNormal">REPOR=
T CHILD ABUSE OR NEGLECT
SAFE (#7233) from a cell phone or 1-855-333-SAFE .<=
/span><span style=3D"font-size:10.0pt;font-family:"Arial";"=
t;sans-serif";color:#1F497D"><o:p></o:p></p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:"=
;Arial";"sans-serif";color:#1F497D"><o:p> </o:p>=
</p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:"=
;Arial";"sans-serif";color:#1F497D">Confidentiality Notice:<=
/span><span style=3D"font-size:10.0pt;font-family:"Arial";&qu=
ot;sans-serif";color:#1F497D"> This e-mail, including all attach=
ments is
for the sole use of the intended recipient[s] and may contain confidential=
and/or privileged information. Any unauthorized use, copying, disclo=
sure or distribution is prohibited, unless specifically provided under New =
Mexico Inspection of Public Records Act.
If you are not the intended recipient, please contact the sender at once a=
nd destroy all copies of this message.=
<o:p></o:p></p>
</div>
<p class=3D"MsoNormal"><o:p> </o:p></spa=
n></p>
<div>
<div style=3D"border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in =
0in 0in">
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:"=

;Tahoma";,"sans-serif";">From: Kesner, = Ben., RLD

Sent: Thursday, May 21, 2015 2:55 PM

To: Swatek, Joshua, DOH; Heinz Bennett, Melissa, DOH

Subject: RE: Naloxone<o:p></o:p></p>

</div>

</div>

<p class=3D"MsoNormal"><o:p> </o:p></p>

<p class=3D"MsoNormal">Hi Josh,<o:p></o:p></p>

<p class=3D"MsoNormal"><o:p> </o:p></p>

<p class=3D"MsoNormal">I appreciate the thought you put into this. I agree with the majority of your changes.<o:p></o:p></p>

<p class=3D"MsoNormal">The part I disagree with is the NM Medical Board.<o:p></o:p></p>

<p class=3D"MsoNormal">This is necessary in order to have this type of facility possess opioid antagonist.<o:p></o:p></p>

<p class=3D"MsoNormal">I reviewed the statutes and regulations you provided.<o:p></o:p></p>

<p class=3D"MsoNormal">And I agree, you can administer Naloxone.<o:p></o:p></p>

<p class=3D"MsoNormal">However, the issue is how to have a CBO Licensed Care Facility have authorization to possess a dangerous drug.<o:p></o:p></p>

<p class=3D"MsoNormal">Ideally, we would have a legislative change.<o:p></o:p></p>

<p class=3D"MsoNormal">But, as we discussed, we possibly could have the NMMB reduce restrictions.<o:p></o:p></p>

<p class=3D"MsoNormal">This is still iffy.<o:p></o:p></p>

<p class=3D"MsoNormal"><o:p> </o:p></p>

<p class=3D"MsoNormal">Thanks, Ben<o:p></o:p></p>

<p class=3D"MsoNormal"><o:p> </o:p></p>

<div>

<p class=3D"MsoNormal">Ben Kesner<o:p></o:p></p>

<p class=3D"MsoNormal">Executive Director<o:p></o:p></p>

<p class=3D"MsoNormal">Regulation and Licensing Department<o:p></o:p></p>

<p class=3D"MsoNormal">New Mexico Board of Pharmacy<o:p></o:p></p>

<p class=3D"MsoNormal">(505) 222-9838 - Office<o:p></o:p></p>

<p class=3D"MsoNormal">(505) 222-9845 - Fax<o:p></o:p></p>

<p class=3D"MsoNormal">ben.kesner@state.nm.us<o:p></o:p></p>

<p class=3D"MsoNormal">www.rld.state.nm.us/pharmacy<o:p></o:p></p>

REPORT CHILD ABUSE OR NEGLECT

SAFE (7233) from a cell phone or 1-855-333-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act.

If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Swatek, Joshua, DOH

Sent: Thursday, May 21, 2015 2:17 PM

To: Kesner, Ben., RLD; Heinz Bennett, Melissa, DOH

Subject: RE: Naloxone

Good Afternoon,

Sorry it has taken me some time to get back with you on this, I've been out of the office due to a family emergency and just got the chance to take a look at it. A lot of it looks very similar to what I had down and didn't get the chance to send out due my time out of the office. I did make a few minor changes to the naloxone section, I'm not comfortable enough with school based regulations to make changes on that, primarily I simplified the definition of a CBO licensed facility, and moved the limitations of ownership into the CBO section itself. I also removed the NM board standing order portion. To the best of my understanding there is not a standing order needed for the administration of naloxone as there is a statute and regulation that already provides for that with 24-23-1 NMSA 1978 and NMAC 7.32.7. I also removed mention of naloxone and replaced it with opioid antagonist, again this would allow for another potential antagonist to be used if one became available and

<o:p> </o:p>

Confidentiality Notice: This e-mail, including all attachments is

for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. </p><p>Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. </p>

If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.<o:p></o:p></p>

<p class="MsoNormal"><o:p> </o:p></p>

</div>

</body>

</html>

--_000_7472697378727672757172686868696974696970807680797070787_--